• Boundless Bio Presents Data on Extrachromosomal DNA Driven Resistance to KRASG12C Inhibitors at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

    17 days ago - By San Diego Biotechnology

    SAN DIEGO--Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in aggressive cancers, today will present a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The poster, LBA005: Detection of KRAS amplification on extrachromosomal DNA upon acquired resistance...
    Read more ...